about
Personalizing health care: feasibility and future implications.The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007)Genetic signatures of heroin addiction.Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome.Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Review of the clinical studies using the 21-gene assay.
@ast
Review of the clinical studies using the 21-gene assay.
@en
type
label
Review of the clinical studies using the 21-gene assay.
@ast
Review of the clinical studies using the 21-gene assay.
@en
prefLabel
Review of the clinical studies using the 21-gene assay.
@ast
Review of the clinical studies using the 21-gene assay.
@en
P2093
P2860
P1433
P1476
Review of the clinical studies using the 21-gene assay
@en
P2093
Catherine M Kelly
Daphne T Tsoi
Ellen Warner
Sunil Verma
P2860
P304
P356
10.1634/THEONCOLOGIST.2009-0277
P577
2010-04-26T00:00:00Z